Protara Therapeutics Inc. (TARA)
NASDAQ: TARAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TARA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $140.38M
- EPS (TTM)
- -$1.39
- Dividend yield
- None
- 52-week range
- 2.09 – 7.82
- Day range
- 2.25 – 2.42
- Volume / Avg
- 1.07M / 1.07M
- Beta
- —
- Shares outstanding
- 61.57M
52-week range
TARA stock today
Shares of Protara Therapeutics (TARA) finished lower on Nov 20 at $2.28, a drop of 5.00% or $0.12 per share, versus the S&P 500's 3.70% decline. At this level, TARA sits near the bottom of its 52-week range of $2.09 to $7.82: 70.8% below the high, set on Nov 24, 2025 and 9.1% above the low. TARA is down 57.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 68.6%.
Protara Therapeutics has posted a net loss over the last twelve months (EPS of -$1.39), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Protara Therapeutics
Company profileProtara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Jesse Shefferman
- Headquarters
- New York, NY
- Employees
- 46
- IPO year
- 2014
- Website
- protaratx.com
Financial highlights
Full financialsProtara Therapeutics reported a net loss of $57.4 million, compared with a loss of $44.6 million a year earlier. Diluted earnings per share came in at -$1.34.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-57.44M | $-44.60M | $-40.42M | $-65.95M | $-47.25M |
| EPS (diluted) | $-1.34 | $-2.17 | $-3.57 | $-5.86 | $-4.21 |
Analyst forecast
ForecastConsensus (8 analysts)
strong_buy
Avg. price target
$25.33+1010.96%
- Strong buy 2
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-0.35 vs $-0.37
- Surprise
- +5.41%
TARA news
All TARA newsProtara Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| STROSutro Biopharma Inc. | 8.60 | -1.38% | $142.77M | vs TARA |
| PALIPalisade Bio Inc. | 0.8399 | -9.24% | $150.74M | vs TARA |
| CMPXCompass Therapeutics Inc. | 0.6882 | +1.43% | $123.94M | vs TARA |
| HUMAHumacyte Inc. | 0.4454 | -17.90% | $123.73M | vs TARA |
| IVVDInvivyd Inc. | 0.4127 | -7.45% | $122.01M | vs TARA |
| ENGNenGene Therapeutics Inc. | 1.74 | -1.14% | $116.61M | vs TARA |
| ARMPArmata Pharmaceuticals Inc. | 3.03 | +1.68% | $112.69M | vs TARA |
| FATEFate Therapeutics Inc. | 0.919 | -9.01% | $111.82M | vs TARA |
Indexes, lists and sector
Protara Therapeutics stock FAQ
What is Protara Therapeutics's stock price today?
TARA last traded at $2.28 as of Nov 20, 4:00 PM EST, down 5.00% on the day. Prices are delayed at least 15 minutes.
Does Protara Therapeutics pay a dividend?
No. Protara Therapeutics does not currently pay a regular cash dividend.
Who is Protara Therapeutics's CEO?
Mr. Jesse Shefferman is the chief executive officer of Protara Therapeutics Inc., which has about 46 employees.
Has TARA ever split its stock?
Yes. The most recent TARA stock split was a 1-for-40 split on Jan 10, 2020.
What is the TARA 52-week high?
The 52-week high for TARA is $7.82 and the 52-week low is $2.09. The stock is currently 70.8% below its high.